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Postmenopausal bleeding (PMB) is a common clinical problem. Patients with PMB have 10%–15% chance of having endometrial
carcinoma and therefore the diagnostic workup is aimed at excluding malignancy. Patient characteristics can alter the probability
of having endometrial carcinoma in patients with PMB; in certain groups of patients the incidence has been reported to be as
high as 29%. Transvaginal sonography (TVS) is used as a first step in the diagnostic workup, but different authors have come
to different conclusions assessing the accuracy of TVS for excluding endometrial carcinoma. Diagnostic procedures obtaining
material for histological assessment (e.g., dilatation and curettage, hysteroscopy, and endometrial biopsy) can be more accurate
but are also more invasive. The best diagnostic strategy for diagnosing endometrial carcinoma in patients with PMB still remains
controversial. Future research should be focussed on achieving a higher accuracy of different diagnostic strategies.
1. Introduction
Postmenopausal bleeding (PMB) can be defined as uterine
bleeding occurring at least one year after menopause. PMB
is a common clinical problem in both general and hospital
settings [1, 2]. The incidence of spontaneously occurring
PMB in the general population can be as high as 10%
immediately after menopause [3].
PMB is often caused by abnormalities of the end-
ometrium, whether they are benign or malignant. Of
postmenopausal women with vaginal bleeding, 10%–15%
have endometrial carcinoma [4–8]. In contrast, the preva-
lence of endometrial polyps in patients with PMB and an
increased endometrial thickness measured with transvaginal
sonography (TVS) is estimated to be around 40% [9, 10].
Endometrial cancer is the most common malignancy of
the female genital tract in developed countries [11]. Unlike
other malignancies, endometrial cancer often presents at an
early stage when there is a possibility of curative treatment by
hysterectomy. Survival decreases with increased staging and
lower histological differentiation, thus accurate and timely
diagnosis is important and should preferably be carried out
by a safe, simple and minimally invasive method. Guidelines
addressing PMB are therefore aimed at excluding cervical
cancer, endometrial carcinoma or precancerous lesions of the
endometrium [12–15].
2. Diagnosis of Endometrial Carcinoma
2.1. Accuracy of Transvaginal Ultrasonography for Diagnos-
ing Endometrial Carcinoma. Since two decades TVS has
become widely used in the evaluation of women with PMB.
Before TVS was introduced in the early 1990s, women
with PMB were scheduled for dilatation and curettage
(D&C). The goal of TVS assessment of the endometrium
is to exclude endometrial carcinoma. The probability of
endometrial pathology is strongly reduced in the presence
of an endometrial ultrasound with an endometrial thickness
≤4 mm. Endometrial sampling is not recommended below
this cutoff value [16–18].
Guidelines [12–15] almost always refer to a meta-analysis
performed by Smith-Bindman et al. [17]. Although this is the
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most cited publication, there are three meta-analyses on this
subject which have used different methods and have come to
different conclusions [16–18].
The meta-analysis of Smith-Bindman et al. [17] com-
bined published data from different studies. Using the
reported data, 2 × 2 tables per included study were con-
structed that compared endometrial thickness measured
at TVS to presence or absence of endometrial carcinoma.
Results across studies were combined in a summary Receiver
Operator Characteristics (ROC) Curve. At a 5 mm cutoff the
sensitivity for detecting endometrial cancer was 96% for a
39% false-positive rate. Such a combination of sensitivity
and specificity would reduce a pretest probability of 10%
for endometrial cancer to a posttest probability of 1% [17].
Based on this posttest probability, expectant management is
at present recommended to these women.
Gupta et al. [16] conducted a comprehensive systematic
review in which they focused on the study quality assessment
of each study. Only four studies were identified as best-
quality studies [19–22]. For each paper a 2 × 2 table was
constructed and likelihood ratios (LR) were calculated.
Pooling of the results of these four studies for endometrial
thickness ≤5 mm resulted in a LR of a negative test of 0.16.
In a patient with a negative test result, the posttest probability
was 2.5% [16].
Tabor et al. [18] included only studies from which they
were able to get the original data from the authors. For
each study they calculated median endometrial thickness per
centre and used multiples of the median for endometrial
thickness to pool data. They reported a sensitivity of 96%
for a specificity of 50% and concluded that such a sensitivity
with a 4% false-negative rate was too high. Therefore, in their
opinion endometrial thickness measurement does not reduce
the need for invasive diagnostic testing [18].
Besides the test accuracy, the pretest probability (before
any test is done) influences the performance of a diag-
nostic test in clinical practice. The pretest probability is
approximately 10% for the whole population of patients with
PMB, but various clinical characteristics can alter this pretest
probability. The probability of endometrial carcinoma in
women with PMB rises from 1% in women younger than
50 years to 23.8% in women older than 80 years and the
incidence of malignancy is, regardless of age, higher in
women with PMB and obesity (18%) or diabetes (21%) as
compared to women without one of these risk factors (8.0%)
[23]. In obese women with diabetes the incidence is reported
to be as high as 29% [23]. As the pretest probability for
malignancy is higher, the potential of the test to reduce the
posttest probability to below 5% can be limited.
2.2. Accuracy of Invasive Endometrial Assessment Methods.
Patients with an increased endometrial thickness should
undergo more invasive testing, that is, office endometrial
sampling, hysteroscopy or dilation and curettage (D&C), to
exclude endometrial pathology.
D&C was traditionally the method of choice for investi-
gating patients with postmenopausal bleeding. However, in
approximately 60% of the D&C procedures less than half of
the uterine cavity is curetted. Another drawback of D&C is
that this procedure is performed under general anaesthesia
in an inpatient setting [24]. D&C is now considered to be
outdated practice and is replaced by less invasive outpatient
evaluation using endometrial biopsy devices and outpatient
hysteroscopy guided biopsies [25].
Guidelines advocate office endometrial sampling to rule
out endometrial carcinoma in women with PMB and
an increased endometrial thickness, measured with TVS.
Dijkhuizen et al. [26] performed a meta-analysis comparing
different minimally invasive endometrial biopsy devices. In
postmenopausal women endometrial sampling with both the
Pipelle device (Pipelle de Cornier, Paris, France) and the
Vabra device (Berkeley Medevices, Inc., Richmond, Calif,
USA) are very sensitive techniques for the detection of
endometrial carcinoma, with detection rates of 99.6% and
97.1%, respectively, [26]. Despite these reassuring features,
the amount of tissue obtained by office sampling varies
considerably and is sometimes insufficient for a reliable
histological diagnosis. In case the material is classified as
insufficient, the clinician is in doubt whether or not to
proceed with more invasive testing or to rely on the negative
biopsy. In a prospective study performed by Van Doorn
et al. four (6%) out of 66 patients with insufficient tissue
at office endometrial sample were subsequently diagnosed
with endometrial cancer (n = 3) or atypical hyperplasia (n =
1). This finding implicates that women with an insufficient
sample and an endometrial thickness of 5 mm or more
should not be reassured [27].
Compared with traditional methods such as curettage,
hysteroscopy offers the possibility of visualizing macroscopic
or focal abnormalities and taking directed biopsies [28, 29].
With the development of smaller diameter hysteroscopic
systems and the introduction of a “vaginoscopic” approach
to hysteroscopy (without the use of a speculum or tenac-
ulum), patient acceptance has improved considerably and
hysteroscopy nowadays can be performed in an outpatient
setting without the use of anaesthesia [30, 31].
3. Diagnostic Strategies for
Postmenopausal Bleeding
In clinical practice, tests are commonly combined in diagnos-
tic sequences and disease probabilities are usually estimated
in a hierarchical manner, first combining information from
history and patient characteristics followed by information
from additional testing. Test accuracy studies often do not
take this clinical paradigm into account. They usually report
on the status of a test disregarding history and patient
characteristics. Assessing tests in isolation of other tests
in the diagnostic sequence (including information from
clinical history and patient characteristics) exaggerates the
diagnostic information that test combinations can provide
in practice.
To determine the most cost-effective testing strategy for
diagnosing endometrial carcinoma in women with PMB,
Clark et al. constructed a decision model and evaluated
12 different strategies for the initial investigation of PMB.
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Figure 1: Possible diagnostic pathways for postmenopausal bleeding. The areas surrounded by a dotted square require futher research.
Depending on cancer prevalence (5% versus 10%, resp.), a
strategy with TVS as initial investigation with a cut-off of
5 mm or 4 mm followed by endometrial biopsy was most cost
effective [1].
There is considerable variability in the endometrial
thickness and the likelihood of endometrial carcinoma across
women. This variability has been associated with individual
patient characteristics including age, time since menopause,
obesity, hypertension, diabetes mellitus, and reproductive
factors [23, 32–36]. However, guidelines currently used
are mainly based on endometrial thickness only, and do
not systematically take these additional characteristics into
account [12–15].
Inclusion of these individual characteristics may allow
for a more refined differentiation of women with the
same endometrial thickness. This could result in a more
individualised and possibly more accurate and efficient
work-up strategy, in which a very high a priori chance of
endometrial carcinoma warrants further histological testing,
whereas women with a very low prior chance might be
reassured even without TVS.
Multivariable models to predict endometrial carcinoma
incorporating patient characteristics in the diagnostic work-
up for patients with PMB have been developed [37–40].
Khan et al. proposed the use of individual patient data meta
analysis in developing these multivariable models to calculate
a posttest probability of disease for a different combination of
test results (including patient characteristics and information
from clinical history) [38].
Figure 1 shows an algorithm with possible diagnostic
pathways for PMB. In this figure an evidence-based approach
is combined with approaches requiring more research. Two
areas require further research: (1) probability modelling to
calculate the pretest probability of endometrial cancer based
on patient characteristics [37] and the implementation of
such a model in the diagnostic strategy and finally imple-
mentation into daily practice and (2) diagnostic approach to
benign pathology. That is wether or not subsequent endome-
trial cavity evaluation for benign abnormalities should be
performed after malignancy has been ruled out [41].
4. General Conclusions and Future Research
Sensitivity of TVS endometrial thickness measurement in
women with PMB is still controversial. Future research
should aim at achieving a higher accuracy of the diagnostic
strategy applied. Such higher accuracy might be achieved by
incorporation of patient’s characteristics (e.g., age, presence
of diabetes, Body Mass Index (BMI), presence of hyper-
tension) in the diagnostic work-up. The incorporation of
TVS with patient’s characteristics in a diagnostic strategy
has been studied and resulted in higher diagnostic accuracy
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[37, 39, 40]. Statistical methods can be used to develop and
further improve such models and incorporating patient’s
characteristics with diagnostic tests [38, 40]. Furthermore,
by combining and analysing individual patient data from
different studies (IPD meta analyses), larger databases can be
obtained, in which previously described models can be exter-
nally validated [38, 42]. Such models could be incorporated
in clinical prediction rules, where the individual probability
for endometrial cancer is obtained for each individual
woman, and a diagnostic algorithm is developed to maximize
the diagnostic accuracy at an acceptable patient burden and
health care costs. Such prediction rules are currently also
available in reproductive medicine, and comparable to the
risk of malignancy index in ovarian tumours [43, 44]. After
developing such clinical prediction rules, diagnostic accuracy
and clinical applicability should be tested in clinical practice
in a prospective multicentre study. If indeed, such model;
would lead to higher diagnostic accuracy than TVS alone,
office endometrial sampling or office hysteroscopy could
then be offered only to those women with a high probability
of endometrial cancer and its precursors.
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